Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04013672
Recruitment Status : Active, not recruiting
First Posted : July 10, 2019
Last Update Posted : March 17, 2021
Sponsor:
Information provided by (Responsible Party):
David Peereboom, MD, Case Comprehensive Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 2021
Estimated Study Completion Date : May 2021